STOCK TITAN

AlloVir Inc - ALVR STOCK NEWS

Welcome to our dedicated news page for AlloVir (Ticker: ALVR), a resource for investors and traders seeking the latest updates and insights on AlloVir.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AlloVir's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AlloVir's position in the market.

Rhea-AI Summary
AlloVir, Inc. (Nasdaq: ALVR) discontinues three Phase 3 posoleucel studies after DSMB futility analyses. No safety concerns identified. Company to prioritize capital preservation and review strategic options. AlloVir reported $213.3 million in cash, cash equivalents, and short-term investments as of September 30, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-67.17%
Tags
-
Rhea-AI Summary
AlloVir, Inc. (Nasdaq: ALVR) to participate in fireside chat at Piper Sandler 35th Annual Healthcare Conference. CEO Diana Brainard, M.D. to present at 10:00 a.m. ET on November 28, 2023. Webcast and replay available on AlloVir website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.79%
Tags
conferences
-
Rhea-AI Summary
AlloVir, Inc. reports financial results for Q3 2023, with progress in Phase 3 trials of posoleucel and significant financial resources. Three Phase 3 trials for posoleucel are enrolling globally, with topline data expected in H2 2024. AlloVir aims to deliver a transformative therapy for immunocompromised patients. Recent highlights include positive Phase 2 trial results and completion of enrollment in a Phase 1b/2a trial. As of September 30, 2023, AlloVir had $213.3 million in cash, cash equivalents, and short-term investments.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.64%
Tags
Rhea-AI Summary
AlloVir, Inc. CEO to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7%
Tags
conferences
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.32%
Tags
-
Rhea-AI Summary
AlloVir, Inc. announces the pricing of an underwritten public offering of 20,000,000 shares of its common stock at a price of $3.75 per share, expected to raise $75.0 million in gross proceeds.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.7%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-35.7%
Tags
-
Rhea-AI Summary
AlloVir presents final results from Phase 2 study of posoleucel for the treatment of BK viremia in kidney transplant recipients
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.63%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.97%
Tags
management
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.36%
Tags
AlloVir Inc

Nasdaq:ALVR

ALVR Rankings

ALVR Stock Data

84.42M
38.30M
48.95%
46.26%
5.49%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
US
Waltham

About ALVR

allovir, inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific t cell (vst) therapies to prevent and treat devastating viral-associated diseases. the company's lead product is viralym-m, an allogeneic, off-the-shelf vst therapy, to treat bk virus, cytomegalovirus, adenovirus, epstein-barr virus, and human herpesvirus 6. its preclinical and clinical development product candidates include alvr106 for respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; alvr109 to treat sars-cov-2 and covid-19; alvr107 for treating hepatitis b; and alvr108 to treat human herpesvirus-8, including kaposi's sarcoma, primary effusion lymphoma, and multicentric castleman's diseases. the company was formerly known as viracyte, inc. and changed its name to allovir, inc. in may 2019. allovir, inc. was founded in 2013 and is based in cambridge, massachusetts.